179 related articles for article (PubMed ID: 30481559)
21. A physiologically-based nanocarrier biopharmaceutics model to reverse-engineer the in vivo drug release.
Nagpal S; Braner S; Modh H; Tan AXX; Mast MP; Chichakly K; Albrecht V; Wacker MG
Eur J Pharm Biopharm; 2020 Aug; 153():257-272. PubMed ID: 32589926
[TBL] [Abstract][Full Text] [Related]
22. Reformulation of Fungizone by PEG-DSPE Micelles: Deaggregation and Detoxification of Amphotericin B.
Alvarez C; Shin DH; Kwon GS
Pharm Res; 2016 Sep; 33(9):2098-106. PubMed ID: 27198671
[TBL] [Abstract][Full Text] [Related]
23. [Liposomal amphotericin B: a unique pharmacokinetic profile. An unfinished story].
Azanza Perea JR; Barberán J
Rev Esp Quimioter; 2012 Mar; 25(1):17-24. PubMed ID: 22488537
[TBL] [Abstract][Full Text] [Related]
24. The Viscoelastic Properties of the Fungal Cell Wall Allow Traffic of AmBisome as Intact Liposome Vesicles.
Walker L; Sood P; Lenardon MD; Milne G; Olson J; Jensen G; Wolf J; Casadevall A; Adler-Moore J; Gow NAR
mBio; 2018 Feb; 9(1):. PubMed ID: 29437927
[TBL] [Abstract][Full Text] [Related]
25. Biodistribution and
Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182
[TBL] [Abstract][Full Text] [Related]
26. Surface-Modified Liposomal Formulation of Amphotericin B: In vitro Evaluation of Potential Against Visceral Leishmaniasis.
Patere SN; Pathak PO; Kumar Shukla A; Singh RK; Kumar Dubey V; Mehta MJ; Patil AG; Gota V; Nagarsenker MS
AAPS PharmSciTech; 2017 Apr; 18(3):710-720. PubMed ID: 27222025
[TBL] [Abstract][Full Text] [Related]
27. AmBisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety/efficacy.
Takemoto K; Kanazawa K
J Liposome Res; 2017 Sep; 27(3):186-194. PubMed ID: 27328721
[TBL] [Abstract][Full Text] [Related]
28. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
29. Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia.
Johansen HK; Gotzsche PC
Cochrane Database Syst Rev; 2000; (3):CD000969. PubMed ID: 10908480
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the pharmacokinetic profiles of two different amphotericin B formulations in healthy dogs.
Bingöl B; Bakirel T
J Vet Pharmacol Ther; 2018 Feb; 41(1):e16-e21. PubMed ID: 28815733
[TBL] [Abstract][Full Text] [Related]
31. In-vitro effects of liposome-encapsulated amphotericin B (AmBisome) and amphotericin B-deoxycholate (Fungizone) on the phagocytic and candidacidal function of human polymorphonuclear leucocytes.
Pallister CJ; Johnson EM; Warnock DW; Elliot PJ; Reeves DF
J Antimicrob Chemother; 1992 Sep; 30(3):313-20. PubMed ID: 1452496
[TBL] [Abstract][Full Text] [Related]
32. Biodegradable functional polycarbonate micelles for controlled release of amphotericin B.
Wang Y; Ke X; Voo ZX; Yap SSL; Yang C; Gao S; Liu S; Venkataraman S; Obuobi SAO; Khara JS; Yang YY; Ee PLR
Acta Biomater; 2016 Dec; 46():211-220. PubMed ID: 27686042
[TBL] [Abstract][Full Text] [Related]
33. Liposomal Amphotericin B Formulation Displaying Lipid-Modified Chitin-Binding Domains with Enhanced Antifungal Activity.
Taniguchi H; Ishimime Y; Minamihata K; Santoso P; Komada T; Saputra H; Uchida K; Goto M; Taira T; Kamiya N
Mol Pharm; 2022 Nov; 19(11):3906-3914. PubMed ID: 36066555
[TBL] [Abstract][Full Text] [Related]
34. Role of In Vitro Release Methods in Liposomal Formulation Development: Challenges and Regulatory Perspective.
Solomon D; Gupta N; Mulla NS; Shukla S; Guerrero YA; Gupta V
AAPS J; 2017 Nov; 19(6):1669-1681. PubMed ID: 28924630
[TBL] [Abstract][Full Text] [Related]
35. Preparation, Characterization, and In Vivo Pharmacokinetic Study of the Supercritical Fluid-Processed Liposomal Amphotericin B.
Lim CB; Abuzar SM; Karn PR; Cho W; Park HJ; Cho CW; Hwang SJ
Pharmaceutics; 2019 Nov; 11(11):. PubMed ID: 31717352
[TBL] [Abstract][Full Text] [Related]
36. Formulation and optimization of nanoemulsion using antifungal lipid and surfactant for accentuated topical delivery of Amphotericin B.
Hussain A; Singh VK; Singh OP; Shafaat K; Kumar S; Ahmad FJ
Drug Deliv; 2016 Oct; 23(8):3101-3110. PubMed ID: 27854145
[TBL] [Abstract][Full Text] [Related]
37. Liposomal drug delivery system from laboratory to clinic.
Kshirsagar NA; Pandya SK; Kirodian GB; Sanath S
J Postgrad Med; 2005; 51 Suppl 1():S5-15. PubMed ID: 16519249
[TBL] [Abstract][Full Text] [Related]
38. [Amphotericin B deoxycholate (Fungizone): old drug, new versions].
Chavanet P
Rev Med Interne; 1997; 18(2):153-65. PubMed ID: 9092035
[TBL] [Abstract][Full Text] [Related]
39. Treatment of neonatal candidiasis with liposomal amphotericin B(L-AMP-LRC-1): phase II study.
Kotwani RN; Bodhe PV; Kirodian BG; Mehta KP; Ali US; Kshirsagar NA
Indian Pediatr; 2003 Jun; 40(6):545-50. PubMed ID: 12824664
[TBL] [Abstract][Full Text] [Related]
40. Tissue pharmacokinetics and pharmacodynamics of AmBisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimens.
Adler-Moore JP; Proffitt RT; Olson JA; Jensen GM
J Liposome Res; 2017 Sep; 27(3):195-209. PubMed ID: 28480760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
